Publikationen in Zusammenarbeit mit Forschern von University of Tasmania (15)

2023

  1. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

    Blood Advances, Vol. 7, Núm. 17, pp. 4926-4935

2021

  1. A Decade of Incorporating Social Sciences in the Integrated Marine Biosphere Research Project (IMBeR): Much Done, Much to Do?

    Frontiers in Marine Science, Vol. 8

  2. Shark mortality cannot be assessed by fishery overlap alone

    Nature

2019

  1. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study

    Arthritis Research and Therapy, Vol. 21, Núm. 1

  2. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

2018

  1. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

    Nature Communications, Vol. 9, Núm. 1

  2. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

    Nature Communications, Vol. 9, Núm. 1

2017

  1. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

    Arthritis and Rheumatology, Vol. 69, Núm. 9, pp. 1903-1913

  2. Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study

    Pharmacogenomics Journal, Vol. 17, Núm. 4, pp. 312-318

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2013

  1. Lessons from the Hvidoere International Study Group on childhood diabetes: Be dogmatic about outcome and flexible in approach

    Pediatric Diabetes, Vol. 14, Núm. 7, pp. 473-480

2012

  1. Closing the case of APOE in multiple sclerosis: No association with disease risk in over 29 000 subjects

    Journal of Medical Genetics, Vol. 49, Núm. 9, pp. 558-562

  2. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  3. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196